Effect of Conditioning Regimen Intensity on Cytomegalovirus Infection and Related Risk Factors Analysis in Allogeneic Hematopoietic Stem Cell Transplantation |
Lee, Hye-Min
(Department of Pharmacy, Samsung Medical Center)
Heo, Yoon-Jeong (Department of Pharmacy, Samsung Medical Center) Im, Hyun-Jeong (Department of Pharmacy, Samsung Medical Center) Chung, Seon-Young (Department of Pharmacy, Samsung Medical Center) In, Yong-Won (Department of Pharmacy, Samsung Medical Center) Jung, Chul-Won (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Young-Mee (Department of Pharmacy, Samsung Medical Center) Sohn, Kie-Ho (College of Pharmacy, Kyungsung University) |
1 | Oh SJ, Lee KH, Lee JH, et al., The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004; 19(2): 172-176. DOI ScienceOn |
2 | Choi SM, Lee DG, Choi JH, et al., Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea. Int J Hematol 2005; 81(1): 69-74. DOI ScienceOn |
3 | Kim YK, Kim DW. Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anticomplement immuno fluorescence technique. Korean J Infect Dis 1992; 24: 87-92. |
4 | Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: What have we learned over the last 10 years?, Hematology Am Soc Hematol Educ Program 2005; 384-389. |
5 | Giralt S, Ballen K, Rizzo D, et al., Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15(3): 367-369. DOI ScienceOn |
6 | National Comprehensive Cancer Network. NCCN Guidelines for Supportive Care. Prevention and Treatment of Cancer-Related Infections v2. 2009. Available from: http:// www.nccn.org/professionals/physician_gls/f_guidelines. asp#infections |
7 | Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113(23): 5711-5719. DOI ScienceOn |
8 | Schmidt-Hieber M, Schwarch S, Stroux A, et al., Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91(5): 877-885. DOI ScienceOn |
9 | Mohty M, Mohty AM, Blaise D, et al., Cytomegalovirusspecific immune recovery following allogeneic HLA identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004; 33(8): 839-846. DOI ScienceOn |
10 | Mahallawy H, Salah F, Sharkawy N, et al., Level and onset of CMV-pp65 antigenemia as determinants of risk for CMV-related complications in stem cell transplant recipients. J Egypt Natl Canc Inst 2001; 13(4): 259-266. |
11 | Kline J, Pollyea DA, Stock W, et al., Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006; 37(3): 307-310. DOI ScienceOn |
12 | Lamba R, Carrum G, Myers GD, et al., Cytomegalovirus (CMV) infections and CMV- specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005; 36(9): 797-802. DOI ScienceOn |
13 | Chakrabarti S, Mackinnon S, Chopra R, et al., High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99(12): 4357-4363. DOI ScienceOn |
14 | Zaia J, Baden L, Boeckh MJ, et al., Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44(8): 471-482. DOI ScienceOn |
15 | Engemann AM. Hematopoietic Stem Cell Transplantation (HSCT) / Blood and Marrow Transplantation (BMT). 2009 Oncology Pharmacy Preparatory Review Course, American College of Clinical Pharmacy / American Society of Health System Pharmacists, 358-438. |
16 | Cathleen M. Conditioning regimen in hematopoietic stem cell transplantation. In: Ezzone S, Schmit-pokorny K (eds). Blood and Marrow Stem Cell Transplantation: Principles, Practice, And Nursing Insights, 3rd edn. Jones & Bartlett : Sudbury, MA, 2005, 109-146. |
17 | Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34(8): 1094-1097. DOI ScienceOn |
18 | Boeckh M, Nichols WG, Papanicolaou G, et al., Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9(9): 543-558. DOI ScienceOn |
19 | Ljungman P, Reusser P, Camara R de la, et al., Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33(11): 1075-1081. DOI ScienceOn |
20 | Cho EY, Park YS, Lee DH, et al., CMV antigenemia following pediatric hematopoietic stem cell transplantation : risk factors and outcomes. Korean J Pediatr 2006; 49(2): 173-180. DOI |
21 | Satwani P, Baldinger L, Freedman J, et al., Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009; 15(12): 1587-1595. DOI ScienceOn |
22 | George B, Kerridge I, Gilroy N, et al., Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. Bone Marrow Transplant 2010; 45(5): 849-855. DOI ScienceOn |
23 | Schetelig J, Oswald O, Steuer N, et al., Cytomegalovirus infections in allogeneic stem cell recipients after reducedintensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003; 32(7): 695-701. DOI ScienceOn |
24 | Martino R, Caballero MD, Canals C, et al., Reducedintensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28(4): 341-347. DOI ScienceOn |
25 | Nakamura R. Cortez K, Solomon S, et al., High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30(4): 235-242. DOI ScienceOn |
26 | Li CR, Greenberg PD, Gilbert MJ, et al., Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83(7): 1971-1979. |